Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.

Marquis-Gravel G, Roe MT, Turakhia MP, Boden W, Temple R, Sharma A, Hirshberg B, Slater P, Craft N, Stockbridge N, McDowell B, Waldstreicher J, Bourla A, Bansilal S, Wong JL, Meunier C, Kassahun H, Coran P, Bataille L, Patrick-Lake B, Hirsch B, Reites J, Mehta R, Muse ED, Chandross KJ, Silverstein JC, Silcox C, Overhage JM, Califf RM, Peterson ED.

Circulation. 2019 Oct 22;140(17):1426-1436. doi: 10.1161/CIRCULATIONAHA.119.040798. Epub 2019 Oct 21.

PMID:
31634011
2.

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.

Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Schlichthaar H, Klaus B, Ambery PD, Meier JJ, Hirshberg B.

J Clin Endocrinol Metab. 2020 Mar 1;105(3). pii: dgz047. doi: 10.1210/clinem/dgz047.

PMID:
31608926
3.

Path integral molecular dynamics for bosons.

Hirshberg B, Rizzi V, Parrinello M.

Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21445-21449. doi: 10.1073/pnas.1913365116. Epub 2019 Oct 7.

PMID:
31591226
4.

Hydrogenic Stretch Spectroscopy of Glycine-Water Complexes: Anharmonic Ab Initio Classical Separable Potential Calculations.

Sagiv L, Hirshberg B, Gerber RB.

J Phys Chem A. 2019 Oct 3;123(39):8377-8384. doi: 10.1021/acs.jpca.9b05378. Epub 2019 Sep 20.

PMID:
31538481
5.

MDCT Imaging of Acute Bladder Pathology.

Hirshberg B, Rheinboldt M.

Curr Probl Diagn Radiol. 2019 May 9. pii: S0363-0188(18)30321-9. doi: 10.1067/j.cpradiol.2019.05.005. [Epub ahead of print] Review.

PMID:
31142434
6.

Multimodality imaging of acute locoregional and systemic complications in the setting of assisted reproduction.

Hirshberg B, Rheinboldt M.

Emerg Radiol. 2019 Apr;26(2):205-219. doi: 10.1007/s10140-018-01665-w. Epub 2019 Jan 10. Review.

PMID:
30631995
7.

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Jain M, Carlson G, Cook W, Morrow L, Petrone M, White NE, Wang T, Naylor J, Ambery P, Lee C, Hirshberg B.

Diabetologia. 2019 Mar;62(3):373-386. doi: 10.1007/s00125-018-4789-6. Epub 2018 Dec 28.

PMID:
30593607
8.

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).

Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL.

Am J Cardiol. 2019 Jan 1;123(1):145-152. doi: 10.1016/j.amjcard.2018.09.014. Epub 2018 Sep 26.

PMID:
30366601
9.

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.

Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23.

PMID:
29945727
10.

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.

Ambery PD, Klammt S, Posch MG, Petrone M, Pu W, Rondinone C, Jermutus L, Hirshberg B.

Br J Clin Pharmacol. 2018 Oct;84(10):2325-2335. doi: 10.1111/bcp.13688. Epub 2018 Aug 7.

11.

N2O5 at water surfaces: binding forces, charge separation, energy accommodation and atmospheric implications.

Hirshberg B, Rossich Molina E, Götz AW, Hammerich AD, Nathanson GM, Bertram TH, Johnson MA, Gerber RB.

Phys Chem Chem Phys. 2018 Jul 4;20(26):17961-17976. doi: 10.1039/c8cp03022g.

PMID:
29926059
12.

The "Christmas tree" bladder.

Hirshberg BV, Myers DT, Williams TR.

Abdom Radiol (NY). 2018 Dec;43(12):3525-3526. doi: 10.1007/s00261-018-1648-3. Review. No abstract available.

PMID:
29797029
13.

The ribbon sign.

Hirshberg B, Myers DT.

Abdom Radiol (NY). 2018 Dec;43(12):3511-3512. doi: 10.1007/s00261-018-1616-y. Review. No abstract available.

PMID:
29666950
14.

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.

Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW.

Cardiovasc Diabetol. 2017 Sep 13;16(1):113. doi: 10.1186/s12933-017-0595-6. Review.

15.

Trapping and Structural Characterization of the XNO2·NO3- (X = Cl, Br, I) Exit Channel Complexes in the Water-Mediated X- + N2O5 Reactions with Cryogenic Vibrational Spectroscopy.

Kelleher PJ, Menges FS, DePalma JW, Denton JK, Johnson MA, Weddle GH, Hirshberg B, Gerber RB.

J Phys Chem Lett. 2017 Oct 5;8(19):4710-4715. doi: 10.1021/acs.jpclett.7b02120. Epub 2017 Sep 18.

PMID:
28898581
16.

Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.

Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O.

Diabetes Res Clin Pract. 2017 Aug;130:24-33. doi: 10.1016/j.diabres.2016.12.019. Epub 2017 Jan 23.

17.

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.

Sjöstrand M, Wei C, Cook W, Johnsson K, Pollack PS, Stahre C, Hirshberg B.

Diabetes Ther. 2017 Jun;8(3):587-599. doi: 10.1007/s13300-017-0261-8. Epub 2017 Apr 21.

18.

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.

Cahn A, Mosenzon O, Bhatt DL, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Stahre C, Im K, Kanevsky E, Raz I.

Diabetes Obes Metab. 2017 Jul;19(7):1045-1050. doi: 10.1111/dom.12903. Epub 2017 Mar 8.

PMID:
28181728
19.

Approximate Quantum Dynamics using Ab Initio Classical Separable Potentials: Spectroscopic Applications.

Hirshberg B, Sagiv L, Gerber RB.

J Chem Theory Comput. 2017 Mar 14;13(3):982-991. doi: 10.1021/acs.jctc.6b01129. Epub 2017 Feb 24.

PMID:
28177631
20.

COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.

Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B.

Endocr Pract. 2017 Mar;23(3):258-265. doi: 10.4158/EP161323.OR. Epub 2016 Nov 16.

PMID:
27849380
21.

Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Perl S, Cook W, Wei C, Ohman P, Hirshberg B.

Clin Ther. 2016 Dec;38(12):2578-2588. doi: 10.1016/j.clinthera.2016.10.006. Epub 2016 Nov 4.

22.

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I.

Diabetes Care. 2017 Jan;40(1):69-76. doi: 10.2337/dc16-0621. Epub 2016 Oct 17.

23.

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial.

Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA.

JAMA Cardiol. 2016 Dec 1;1(9):989-998. doi: 10.1001/jamacardio.2016.3030.

PMID:
27681000
24.

Formation of Carbonic Acid in Impact of CO2 on Ice and Water.

Hirshberg B, Gerber RB.

J Phys Chem Lett. 2016 Aug 4;7(15):2905-9. doi: 10.1021/acs.jpclett.6b01109. Epub 2016 Jul 18.

PMID:
27420400
25.

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment.

Perl S, Cook W, Wei C, Iqbal N, Hirshberg B.

Diabetes Ther. 2016 Sep;7(3):527-35. doi: 10.1007/s13300-016-0184-9. Epub 2016 Jul 11.

26.

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial.

Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Sjostrand M, Stahre C, Im K, Kanevsky E, Scirica BM, Bhatt DL, Braunwald E.

Diabetes Care. 2016 Aug;39(8):1329-37. doi: 10.2337/dc15-2763. Epub 2016 May 23.

PMID:
27222508
27.

A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.

Bonora E, Bryzinski B, Hirshberg B, Cook W.

Nutr Metab Cardiovasc Dis. 2016 May;26(5):374-9. doi: 10.1016/j.numecd.2015.11.004. Epub 2015 Dec 1.

PMID:
27033025
28.

Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.

Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL.

Am J Med. 2016 Mar;129(3):340.e1-8. doi: 10.1016/j.amjmed.2015.09.022. Epub 2015 Oct 31.

PMID:
26524706
29.

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators.

Circulation. 2015 Oct 13;132(15):e198. doi: 10.1161/CIR.0000000000000330. No abstract available.

PMID:
26459088
30.

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial.

Leiter LA, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

Diabetes Obes Metab. 2016 Feb;18(2):186-90. doi: 10.1111/dom.12582. Epub 2015 Nov 27.

PMID:
26443993
31.

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).

Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B.

Diabetes Metab Res Rev. 2016 Mar;32(3):289-96. doi: 10.1002/dmrr.2717. Epub 2015 Oct 28.

PMID:
26385269
32.

Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.

Hirshberg B, Katz A.

Curr Diab Rep. 2015 Nov;15(11):87. doi: 10.1007/s11892-015-0663-9. Review.

PMID:
26370698
33.

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, Bhatt DL, Raz I.

Diabetes Care. 2015 Nov;38(11):2142-50. doi: 10.2337/dc15-1068. Epub 2015 Sep 10.

PMID:
26358285
34.

Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.

Matthaei S, Catrinoiu D, Celiński A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L.

Diabetes Care. 2015 Nov;38(11):2018-24. doi: 10.2337/dc15-0811. Epub 2015 Aug 31.

PMID:
26324329
35.

Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial".

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg G, Bhatt DL.

Circulation. 2015 Aug 11;132(6):e121-2. doi: 10.1161/CIRCULATIONAHA.115.015511. No abstract available.

PMID:
26260506
36.

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.

Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N.

Diabetes Care. 2015 Nov;38(11):2009-17. doi: 10.2337/dc15-0779. Epub 2015 Aug 5.

PMID:
26246458
37.

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.

Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, Smahelova A, Hirshberg B, Stahre C, Frederich R, Bonnici F, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

Diabetes Care. 2015 Jun;38(6):1145-53. doi: 10.2337/dc14-2868. Epub 2015 Mar 10.

PMID:
25758769
38.

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.

Leibowitz G, Cahn A, Bhatt DL, Hirshberg B, Mosenzon O, Wei C, Jermendy G, Sheu WH, Sendon JL, Im K, Braunwald E, Scirica BM, Raz I.

Diabetes Obes Metab. 2015 May;17(5):487-94. doi: 10.1111/dom.12445. Epub 2015 Feb 25.

PMID:
25656169
39.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.

Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators.

Diabetes Care. 2015 Apr;38(4):696-705. doi: 10.2337/dc14-1850. Epub 2014 Dec 31.

PMID:
25552421
40.

Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes.

Geiger MJ, Mehta C, Turner JR, Arbet-Engels C, Hantel S, Hirshberg B, Koglin J, Mendzelevski B, Sager PT, Shapiro D, Stewart M, Todaro TG, Gaydos B.

Ther Innov Regul Sci. 2015 Jan;49(1):50-64. doi: 10.1177/2168479014549860.

PMID:
30222452
41.
42.

Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.

Hansen L, Iqbal N, Ekholm E, Cook W, Hirshberg B.

Endocr Pract. 2014 Nov;20(11):1187-97. doi: 10.4158/EP14489.OR.

PMID:
25370334
43.
44.

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects.

Gummesson A, Li H, Gillen M, Xu J, Niazi M, Hirshberg B.

Clin Drug Investig. 2014 Nov;34(11):763-72. doi: 10.1007/s40261-014-0230-1.

PMID:
25269885
45.

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.

Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators*.

Circulation. 2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4. Erratum in: Circulation. 2015 Oct 13;132(15):e198.

PMID:
25189213
46.

Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy.

Bryzinski B, Allen E, Cook W, Hirshberg B.

J Diabetes Complications. 2014 Nov-Dec;28(6):887-93. doi: 10.1016/j.jdiacomp.2014.07.006. Epub 2014 Jul 17.

PMID:
25168266
47.

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.

Sjöstrand M, Iqbal N, Lu J, Hirshberg B.

Diabetes Res Clin Pract. 2014 Aug;105(2):185-91. doi: 10.1016/j.diabres.2014.05.006. Epub 2014 May 29.

PMID:
24947443
48.

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.

Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM.

Diabetes Care. 2014 Sep;37(9):2435-41. doi: 10.2337/dc13-2546. Epub 2014 Jun 9.

PMID:
24914244
49.

Ab initio and semi-empirical Molecular Dynamics simulations of chemical reactions in isolated molecules and in clusters.

Gerber RB, Shemesh D, Varner ME, Kalinowski J, Hirshberg B.

Phys Chem Chem Phys. 2014 Jun 7;16(21):9760-75. doi: 10.1039/c3cp55239j. Epub 2014 Feb 26.

50.

Decomposition of condensed phase energetic materials: interplay between uni- and bimolecular mechanisms.

Furman D, Kosloff R, Dubnikova F, Zybin SV, Goddard WA 3rd, Rom N, Hirshberg B, Zeiri Y.

J Am Chem Soc. 2014 Mar 19;136(11):4192-200. doi: 10.1021/ja410020f. Epub 2014 Mar 6.

PMID:
24495109

Supplemental Content

Loading ...
Support Center